ReviewContemporary oncology (Poznan, Poland)2015
Statins and cancers.
Review in Contemporary oncology (Poznan, Poland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer.Anti-cancer agents in medicinal chemistry · 2024Pooled it
- Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery.BMC cancer · 2022Pooled it
- A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2022Pooled it
- Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis.Journal of preventive medicine and hygiene · 2020Pooled it
- Meta-analysis of studies using statins as a reducer for primary liver cancer risk.Scientific reports · 2016Pooled it
- An Overview of the Antioxidant, Anti-inflammatory, and Anticancer Effects of Statins.Anti-cancer agents in medicinal chemistry · 2026Review
- Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.ACS pharmacology & translational science · 2025Review
- CaaX-motif adjacent residues control G protein prenylation under suboptimal conditions.bioRxiv : the preprint server for biology · 2023Article
- Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses.Cancers · 2023Review
- Cholesterol in colorectal cancer: an essential but tumorigenic precursor?Frontiers in oncology · 2023Review
- Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Screening of GPCR drugs for repurposing in breast cancer.Frontiers in pharmacology · 2022Article
- Crosstalk between Statins and Cancer Prevention and Therapy: An Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Association of Pre-Admission Statin Use With Reduced In-Hospital Mortality in COVID-19.The American journal of the medical sciences · 2021Article
- Statins in risk-reduction and treatment of cancer.World journal of clinical oncology · 2020Review
- SCP2-mediated cholesterol membrane trafficking promotes the growth of pituitary adenomas via Hedgehog signaling activation.Journal of experimental & clinical cancer research : CR · 2019Article
- Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- The role of cholesterol metabolism in cancer.American journal of cancer research · 2019Review
- Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins (inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) are a group of drugs used to treat lipid disorders. They inhibit cholesterol synthesis at an early stage of the biosynthesis pathway, thus eliminating numerous metabolites involved in the cycle. Numerous studies point to different possible effects of statins on cancer cells. Statins inhibit growth of a tumor, invasion and metastasis formation. They block the production of isoprenoids, which are necessary for post-translational modifications of many proteins, including those involved in normal cell signaling. They also contribute to the reduction in the expression of vascular endothelial growth factor, sensitize tumor cells to NK cell activity, and modify the body inflammatory response. Due to different pharmacokinetic properties of individual statins, they may have opposite effects on the risk of cancer. Currently, most information on the effects of statins on the risk of developing cancer is obtained from observational studies. The studies have different results depending on the location of cancer. The protective effect of statins was observed in the meta-analysis of numerous studies including prostate cancer, stomach cancer, esophagus cancer, and hepatocellular carcinoma; however, it has not yet been confirmed that statins influence the risk of developing colorectal cancer, breast cancer, or lung cancer. The protective effect of statins on the development of many kinds of cancer can be a valuable and easy way to reduce morbidity. However, further research is necessary to thoroughly determine the value of this group of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.